Geovax Labs Price to Book Value is fairly stable at the moment as compared to the past year. Geovax Labs reported Price to Book Value of 1.35 in 2020. Price to Sales Ratio is likely to rise to 2.63 in 2021, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (3 M) in 2021. While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to break down Geovax Labs. We will analyze why it could be a much better year for Geovax Labs shareholders. This post is to show some fundamental factors affecting Geovax Labs' products and services. I will also show how it may impact the investing outlook for the company in May.
About 5.0% of Geovax Labs shares are owned by
institutional investors. Insiders ownership of Geovax Labs refers to the amount of Geovax Labs equity owned by Geovax officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Geovax, including its current
ownership diagnostics.
GeoVax Labs
financial leverage refers to using borrowed capital as a funding source to finance GeoVax Labs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. GeoVax Labs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to GeoVax Labs' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of GeoVax Labs' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between GeoVax Labs's total debt and its cash.
GeoVax Labs reported
Total Cash From Operating Activities of
(22.66 Million) in 2024. To perform a cash flow analysis of GeoVax Labs, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash GeoVax Labs is receiving and how much cash it distributes out in a given period. The GeoVax Labs cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
GeoVax Labs Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing GeoVax Labs previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show GeoVax Labs Gross Profit growth over the last 10 years. Please check GeoVax Labs'
gross profit and other
fundamental indicators for more details.
The
market capitalization of Geovax Labs is $28.61 Million. Geovax Labs retains 8.32 (percent) if its
outstanding shares held by
insiders and 8.32 (percent) owned by
outside corporations . Note, that even with negative
profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Ownership Breakdown
| Retail Investors87.15% | Insiders8.32% | |
| Retail Investors | 87.15 |
| Insiders | 8.32 |
| Institutions | 4.53 |
Are Geovax Labs technical indicators showing a recoup?
The total risk alpha is down to -1.1 as of today. Geovax Labs is displaying above-average volatility over the selected time horizon. Investors should scrutinize Geovax Labs independently to ensure intended market timing strategies are aligned with expectations about Geovax Labs volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Geovax Labs' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Geovax Labs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
While some other entities in the biotechnology industry are either recovering or due for a correction, Geovax Labs may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 9th of April 2021, we see that Geovax Labs hyperactively responds to market trends. The company is
undervalued with
very low probability of distress within the next 24 months. Our final 30 days 'Buy-vs-Sell' recommendation on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectGabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of GeoVax Labs. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com